http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 07:30:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html <p>Corvus Pharmaceuticals (Nasdaq: CRVS) announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma in <em>Blood</em>, the journal of the American Society of Hematology.</p> <p>The trial enrolled 75 heavily pre-treated patients across multiple T cell lymphoma subtypes, including peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma, and others. The median number of prior therapies was three, ranging from one to 18, with only 31% of patients having achieved an objective response to their most recent prior therapy.</p> <p>A 200 mg twice-daily dose was selected for the expansion portion of the trial http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html Thu, 27 Aug 2026 07:30:42 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html <p>Corvus Pharmaceuticals (Nasdaq: CRVS) announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma in <em>Blood</em>, the journal of the American Society of Hematology.</p> <p>The trial enrolled 75 heavily pre-treated patients across multiple T cell lymphoma subtypes, including peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma, and others. The median number of prior therapies was three, ranging from one to 18, with only 31% of patients having achieved an objective response to their most recent prior therapy.</p> <p>A 200 mg twice-daily dose was selected for the expansion portion of the trial http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html Thu, 27 Aug 2026 07:30:42 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html <p>Corvus Pharmaceuticals (Nasdaq: CRVS) announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma in <em>Blood</em>, the journal of the American Society of Hematology.</p> <p>The trial enrolled 75 heavily pre-treated patients across multiple T cell lymphoma subtypes, including peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma, and others. The median number of prior therapies was three, ranging from one to 18, with only 31% of patients having achieved an objective response to their most recent prior therapy.</p> <p>A 200 mg twice-daily dose was selected for the expansion portion of the trial http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html Thu, 27 Aug 2026 07:30:42 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html <p>Corvus Pharmaceuticals (Nasdaq: CRVS) announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma in <em>Blood</em>, the journal of the American Society of Hematology.</p> <p>The trial enrolled 75 heavily pre-treated patients across multiple T cell lymphoma subtypes, including peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma, and others. The median number of prior therapies was three, ranging from one to 18, with only 31% of patients having achieved an objective response to their most recent prior therapy.</p> <p>A 200 mg twice-daily dose was selected for the expansion portion of the trial http://www.streetinsider.com/FDA/Corvus+Pharmaceuticals+publishes+soquelitinib+Phase+1+T+cell+data+in+Blood/26984763.html Thu, 27 Aug 2026 07:30:42 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html <p align="center"><em>Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma </em></p> <p align="center"><em>Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment</em></p> <p align="center"><em>Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial </em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Announces+Publication+in%C2%A0Blood+of+Final+Phase+1+Data+from+the+Soquelitinib+Phase+11b+T+Cell+Lymphoma+Trial/26984756.html Thu, 27 Aug 2026 07:30:00 -0400 A.32437804 CRVS O.00162576 O.28578323 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corvus+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888442.html si-local-file:///var/storage/secattach/20260807/26888442.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corvus+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888442.html Fri, 07 Aug 2026 09:17:00 -0400 CRVS O.28578323 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corvus+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888442.html si-local-file:///var/storage/secattach/20260807/26888442.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Corvus+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888442.html Fri, 07 Aug 2026 09:17:00 -0400 CRVS O.28578323 http://www.streetinsider.com/Earnings/Corvus+Pharmaceuticals%2C+Inc.+%28CRVS%29+Misses+Q2+EPS+by+4c/26885795.html <p>Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15).</p><p>For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) <a href="http://www.streetinsider.com/ec_earnings.php?q=CRVS">click here</a>.</p> http://www.streetinsider.com/Earnings/Corvus+Pharmaceuticals%2C+Inc.+%28CRVS%29+Misses+Q2+EPS+by+4c/26885795.html Thu, 06 Aug 2026 17:55:10 -0400 CRVS http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Corvus+Pharmaceuticals%2C+++For%3A+Jun+30/26883592.html si-local-file:///var/storage/secattach/20260806/26883592.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Corvus+Pharmaceuticals%2C+++For%3A+Jun+30/26883592.html Thu, 06 Aug 2026 16:05:00 -0400 CRVS O.28578323 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Corvus+Pharmaceuticals%2C+++For%3A+Jun+30/26883592.html si-local-file:///var/storage/secattach/20260806/26883592.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Corvus+Pharmaceuticals%2C+++For%3A+Jun+30/26883592.html Thu, 06 Aug 2026 16:05:00 -0400 CRVS O.28578323 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corvus+Pharmaceuticals%2C+++For%3A+Aug+06/26883356.html si-local-file:///var/storage/secattach/20260806/26883356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corvus+Pharmaceuticals%2C+++For%3A+Aug+06/26883356.html Thu, 06 Aug 2026 16:03:00 -0400 CRVS O.28578323 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corvus+Pharmaceuticals%2C+++For%3A+Aug+06/26883356.html si-local-file:///var/storage/secattach/20260806/26883356.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Corvus+Pharmaceuticals%2C+++For%3A+Aug+06/26883356.html Thu, 06 Aug 2026 16:03:00 -0400 CRVS O.28578323 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html <p align="center"><em>Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track</em></p> <p align="center"><em>Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting</em></p> <p align="center"><em>Cash, </em><em>cash equivalents and marketable securities of </em><em>$215.2 million at June 30, 2026, providing runway into 2Q28</em></p> <p align="center"><em>Conference call and webcast today at 4:30 pm ET / 1:30 pm PT</em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html Thu, 06 Aug 2026 16:01:00 -0400 A.29922014 CRVS O.28578323 O.42081221 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html <p align="center"><em>Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track</em></p> <p align="center"><em>Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting</em></p> <p align="center"><em>Cash, </em><em>cash equivalents and marketable securities of </em><em>$215.2 million at June 30, 2026, providing runway into 2Q28</em></p> <p align="center"><em>Conference call and webcast today at 4:30 pm ET / 1:30 pm PT</em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html Thu, 06 Aug 2026 16:01:00 -0400 A.29922014 CRVS O.28578323 O.42081221 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html <p align="center"><em>Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track</em></p> <p align="center"><em>Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting</em></p> <p align="center"><em>Cash, </em><em>cash equivalents and marketable securities of </em><em>$215.2 million at June 30, 2026, providing runway into 2Q28</em></p> <p align="center"><em>Conference call and webcast today at 4:30 pm ET / 1:30 pm PT</em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html Thu, 06 Aug 2026 16:01:00 -0400 A.29922014 CRVS O.28578323 O.42081221 http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html <p align="center"><em>Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track</em></p> <p align="center"><em>Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting</em></p> <p align="center"><em>Cash, </em><em>cash equivalents and marketable securities of </em><em>$215.2 million at June 30, 2026, providing runway into 2Q28</em></p> <p align="center"><em>Conference call and webcast today at 4:30 pm ET / 1:30 pm PT</em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, http://www.streetinsider.com/Press+Releases/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html Thu, 06 Aug 2026 16:01:00 -0400 A.29922014 CRVS O.28578323 O.42081221 http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html <p align="center"><em>Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track</em></p> <p align="center"><em>Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting</em></p> <p align="center"><em>Cash, </em><em>cash equivalents and marketable securities of </em><em>$215.2 million at June 30, 2026, providing runway into 2Q28</em></p> <p align="center"><em>Conference call and webcast today at 4:30 pm ET / 1:30 pm PT</em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html Thu, 06 Aug 2026 16:01:00 -0400 A.29922014 CRVS O.28578323 O.42081221 http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html <p align="center"><em>Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track</em></p> <p align="center"><em>Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting</em></p> <p align="center"><em>Cash, </em><em>cash equivalents and marketable securities of </em><em>$215.2 million at June 30, 2026, providing runway into 2Q28</em></p> <p align="center"><em>Conference call and webcast today at 4:30 pm ET / 1:30 pm PT</em></p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, http://www.streetinsider.com/Globe+Newswire/Corvus+Pharmaceuticals+Provides+Business+Update+and+Reports+Second+Quarter+2026+Financial+Results/26883260.html Thu, 06 Aug 2026 16:01:00 -0400 A.29922014 CRVS O.28578323 O.42081221